HC Wainwright Reiterates Buy Rating on Phathom Pharmaceuticals
HC Wainwright maintains its buy rating on Phathom Pharmaceuticals with a $26 target.
Key Points
- HC Wainwright reiterated its buy rating on Phathom Pharmaceuticals, setting a price target of $26 on June 17, 2026.
- Phathom Pharmaceuticals trades at $10.43 per share with a market cap of $877.3 million and a forward P/E of 7.64.
- Insiders have been active, with Asit Parikh buying and selling shares in May 2026, and several funds adjusting their holdings.
On June 17, 2026, HC Wainwright reiterated its buy rating on Phathom Pharmaceuticals, Inc. (NasdaqGS: PHAT), setting a price target of $26. This move suggests continued confidence in the biopharmaceutical company's prospects.
What Changed in HC Wainwright's Phathom Pharmaceuticals Position
HC Wainwright's analyst Matthew Caufield reiterated the buy rating without changing the price target, which remains at $26. This suggests that the firm sees potential upside from the current trading price of $10.43.
Other Institutional Activity in Phathom Pharmaceuticals
Several institutional investors have been active in Phathom Pharmaceuticals. Invesco Ltd. increased its stake by 401,614 shares, bringing its total to 4,322,060 shares valued at approximately $48 million. BlackRock, Inc. also boosted its holdings by 506,448 shares, ending with 4,061,996 shares worth about $45.1 million. Millennium Management LLC made a significant addition, buying 1,940,729 shares to hold a total of 4,022,909 shares, valued at $44.7 million.
Phathom Pharmaceuticals Stock Snapshot
Shares of Phathom Pharmaceuticals (NasdaqGS: PHAT) are currently trading at $10.43. The company has a market cap of $877.3 million and a forward P/E ratio of 7.64, indicating potential future earnings growth. The stock's 52-week range is between $7.61 and $18.31, with a beta of 0.51, suggesting lower volatility compared to the market. The 50-day moving average is $11.53, and the 200-day moving average is $12.77.
Recent Earnings
Phathom Pharmaceuticals reported revenue of $204.9 million, showing a growth rate of 4.4%. However, the company is not yet profitable, with a net margin of -76.8%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Phathom Pharmaceuticals, Inc.
Insider activity at Phathom Pharmaceuticals has been notable. On May 22, 2026, Asit Parikh bought and sold 28,000 shares, while on May 20, 2026, he bought 17,500 shares at $4.95 each. Additionally, on May 19, 2026, both Asit Parikh and James Topper each purchased 24,122 shares.
Analysts Set New Price Targets
On June 17, 2026, HC Wainwright reiterated its buy rating with a $26 price target. Previously, on March 27, 2026, Barclays upgraded its rating to buy with an $18 target. Guggenheim maintained a buy rating on February 27, 2026, with a $25 target. The consensus recommendation is a strong buy, with a mean price target of $23.70 from 10 analysts.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and marketing treatments for gastrointestinal diseases in the U.S. The company, headquartered in Florham Park, New Jersey, is led by CEO Steven L. Basta and employs 371 people. Phathom's key products include VOQUEZNA, designed to treat gastroesophageal reflux disease and Helicobacter pylori infections.
Bottom Line
Phathom Pharmaceuticals continues to attract attention from both analysts and institutional investors. HC Wainwright's reaffirmation of its buy rating underlines confidence in the company's potential, despite its current lack of profitability. Investors track these ratings and insider activities to gauge the company's future prospects, but remember that these insights are based on past data and market conditions can change.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.